Cargando…

Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis

CT-P13 is an infliximab biosimilar approved for indications including ankylosing spondylitis (AS); the approved maintenance regimen is 5 mg/kg infused every 6–8 weeks. In clinical practice, modifications to infliximab dose and/or infusion interval can be beneficial to the patient. For CT-P13, real-w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Shin-Seok, Kim, Tae-Hwan, Park, Won, Song, Yeong-Wook, Suh, Chang-Hee, Kim, Soo-Kyoung, Yoo, Dae-Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509762/ https://www.ncbi.nlm.nih.gov/pubmed/34640586 http://dx.doi.org/10.3390/jcm10194568

Ejemplares similares

Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007)

Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score–Matched Analysis from the Korean College of Rheumatology Biologics Registry
por: Kim, Hyoun-Ah, et al.
Publicado: (2020)

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
por: Park, Won, et al.
Publicado: (2017)

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
por: Baji, Petra, et al.
Publicado: (2014)

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
por: Yoo, Dae Hyun, et al.
Publicado: (2017)

Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis
por: Krishnan, V. S. Gokul, et al.
Publicado: (2017)

Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study
por: Park, Eun Hye, et al.
Publicado: (2018)

Body mass index influences the response to infliximab in ankylosing spondylitis
por: Ottaviani, Sébastien, et al.
Publicado: (2012)

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
por: Elalouf, Ofir, et al.
Publicado: (2015)

Bone changes and curative effect of infliximab in patients with ankylosing spondylitis
por: Li, Linying, et al.
Publicado: (2020)

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
por: Park, Won, et al.
Publicado: (2013)

Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2019)

Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
por: Lorenzin, Mariagrazia, et al.
Publicado: (2015)

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis
por: Wang, Chenghai, et al.
Publicado: (2020)

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
por: Park, Won, et al.
Publicado: (2016)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Medical Treatment of Ankylosing Spondylitis
por: Moon, Kyoung-Ho, et al.
Publicado: (2014)

The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis
por: Chopra, Arvind, et al.
Publicado: (2023)

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
por: Mulleman, Denis, et al.
Publicado: (2011)

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
por: Webers, Casper, et al.
Publicado: (2018)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis
por: Keil, Radan, et al.
Publicado: (2016)

The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis
por: Meyer, Antoine, et al.
Publicado: (2019)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
por: Kanters, Tim A., et al.
Publicado: (2017)

Bath Ankylosing Spondylitis Disease Activity Index is Associated With the Quality of Sleep in Ankylosing Spondylitis Patients
por: Song, Byung Wook, et al.
Publicado: (2021)

Higher prevalence of peripheral arthritis among ankylosing spondylitis patients.
por: Lee, Ji-Hyun, et al.
Publicado: (2002)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab
por: Lee, Jeong Seok, et al.
Publicado: (2018)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2018)

The Epidemiology and Treatment of Ankylosing Spondylitis in Korea
por: Kwon, Seong-Ryul, et al.
Publicado: (2022)

The usefulness of trabecular bone score in patients with ankylosing spondylitis
por: Nam, Seoung Wan, et al.
Publicado: (2021)

Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy
por: Szalay, Balázs, et al.
Publicado: (2012)

Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
por: Moreno, Mireia, et al.
Publicado: (2019)

Cerebral Tuberculosis in a Patient Following Treatment With Infliximab for Ankylosing Spondylitis: A Case Report
por: Cretu, Ioana, et al.
Publicado: (2023)

Ankylosing spondylitis
Publicado: (1980)

Cannot write session to /tmp/vufind_sessions/sess_5cga7d62d4rehtde15vni4gcsb